New markers to select children with cancer for trials with PARP inhibitors
Novel biomarkers for PARP inhibitor trials for children with cancer
Developing personalised treatments for brain-directed chemotherapy in childhood acute lymphoblastic leukaemia
ALLTogether1 CSF-FLOW Study
‘Radiogenomics’: A novel non-invasive approach to identify different types of ependymoma brain tumours
Exploring whether a new approach to identifying ependymoma tumours can help support better, more tailored, and potentially less invasive treatment for children with this type of cancer.
Using artificial intelligence to diagnose brain tumours
Moving Artificial Intelligence of Functional Imaging for children’s tumours into a multi-centre environment through a Clinical Decision Support System
Stopping ‘cut-and-run’ DNA errors to help treat leukaemia and predict relapse
Towards inhibiting cut-and-run: An aberrant V(D)J recombination reaction that leads to lymphoid cancers
Improving the outlook for children with Philadelphia positive ALL
Unravelling clinical heterogeneity in Philadelphia positive ALL
"Getting it right first time" for children with renal tumours
Improving prediction of relapse, treatment delivery and outcomes for children with renal tumours in the UK
Finding new drugs to treat high-risk rhabdomyosarcoma
High-risk rhabdomyosarcoma patient derived 3D cultures to screen for novel drugs that enhance sensitivity to standard treatment
Developing a blood test to monitor ependymoma treatment and follow-up
Minimal residual disease detection of ependymoma by microRNA biomarker profile evaluation as part of SIOP Ependymoma II trial